BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34060396)

  • 21. Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases.
    Rybak MY; Balanda AO; Yatsyshyna AP; Kotey IM; Starosyla SA; Bdzhola VG; Lukash LL; Yarmoluk SM; Tukalo MA; Volynets GP
    Sci Rep; 2021 Mar; 11(1):7162. PubMed ID: 33785838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.
    Zhang W; Liu LL; Lun S; Wang SS; Xiao S; Gunosewoyo H; Yang F; Tang J; Bishai WR; Yu LF
    Eur J Med Chem; 2021 Mar; 213():113202. PubMed ID: 33516983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boulton-Katritzky Rearrangement of 5-Substituted Phenyl-3-[2-(morpholin-1-yl)ethyl]-1,2,4-oxadiazoles as a Synthetic Path to Spiropyrazoline Benzoates and Chloride with Antitubercular Properties.
    Kayukova L; Vologzhanina A; Praliyev K; Dyusembaeva G; Baitursynova G; Uzakova A; Bismilda V; Chingissova L; Akatan K
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33673047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
    Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
    Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular properties prediction and synthesis of novel 1,3,4-oxadiazole analogues as potent antimicrobial and antitubercular agents.
    Ahsan MJ; Samy JG; Khalilullah H; Nomani MS; Saraswat P; Gaur R; Singh A
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7246-50. PubMed ID: 22071303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, Spectroscopic, In-vitro and Computational Analysis of Hydrazones as Potential Antituberculosis Agents: (Part-I).
    Thorat BR; Rani D; Yamgar RS; Mali SN
    Comb Chem High Throughput Screen; 2020; 23(5):392-401. PubMed ID: 32209038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents.
    Wu Y; Cheung CY; Zhou Y; Wang Z; Tu Z; Cook GM; Lu X
    Bioorg Med Chem; 2021 Nov; 49():116426. PubMed ID: 34624820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.
    Venugopala KN; Chandrashekharappa S; Pillay M; Bhandary S; Kandeel M; Mahomoodally FM; Morsy MA; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K; Odhav B
    Med Chem; 2019; 15(3):311-326. PubMed ID: 29968540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benzothiazole analogs as potential anti-TB agents: computational input and molecular dynamics.
    Venugopala KN; Khedr MA; Pillay M; Nayak SK; Chandrashekharappa S; Aldhubiab BE; Harsha S; Attimard M; Odhav B
    J Biomol Struct Dyn; 2019 Apr; 37(7):1830-1842. PubMed ID: 29697293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target Mycobacterium tuberculosis.
    Majewski MW; Cho S; Miller PA; Franzblau SG; Miller MJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4933-4936. PubMed ID: 26037320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of inhibitors targeting polyketide synthase 13 of Mycobacterium tuberculosis as antituberculosis drug leads.
    Wang X; Zhao W; Wang B; Ding W; Guo H; Zhao H; Meng J; Liu S; Lu Y; Liu Y; Zhang D
    Bioorg Chem; 2021 Sep; 114():105110. PubMed ID: 34175719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ribosome Rescue Inhibitors Kill Actively Growing and Nonreplicating Persister Mycobacterium tuberculosis Cells.
    Alumasa JN; Manzanillo PS; Peterson ND; Lundrigan T; Baughn AD; Cox JS; Keiler KC
    ACS Infect Dis; 2017 Sep; 3(9):634-644. PubMed ID: 28762275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel 1-(4-substituted benzylidene)-4-(1-(substituted methyl)-2,3-dioxoindolin-5-yl)semicarbazide derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) and MDR-TB strain.
    Raja S; Prakash CR
    Arch Pharm Res; 2013 Apr; 36(4):411-22. PubMed ID: 23440582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds.
    Santos P; Lopez-Vallejo F; Ramírez D; Caballero J; Mata Espinosa D; Hernández-Pando R; Soto CY
    Bioorg Med Chem; 2020 Feb; 28(3):115256. PubMed ID: 31879181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione as antimycobacterial agents.
    Sonawane AD; Rode ND; Nawale L; Joshi RR; Joshi RA; Likhite AP; Sarkar D
    Chem Biol Drug Des; 2017 Aug; 90(2):200-209. PubMed ID: 28083914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a novel class of quinoline-oxadiazole hybrids as anti-tuberculosis agents.
    Jain PP; Degani MS; Raju A; Anantram A; Seervi M; Sathaye S; Ray M; Rajan MGR
    Bioorg Med Chem Lett; 2016 Jan; 26(2):645-649. PubMed ID: 26675440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.